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Eﬀ ect of treatment delay, age, and stroke severity on the 
eﬀ ects of intravenous thrombolysis with alteplase for acute 
ischaemic stroke: a meta-analysis of individual patient data 
from randomised trials
Jonathan Emberson*, Kennedy R Lees*, Patrick Lyden*, Lisa Blackwell, Gregory Albers, Erich Bluhmki, Thomas Brott, Geoﬀ  Cohen, Stephen Davis, 
Geoﬀ rey Donnan, James Grotta, George Howard, Markku Kaste, Masatoshi Koga, Ruediger von Kummer, Maarten Lansberg, Richard I Lindley, 
Gordon Murray, Jean Marc Olivot, Mark Parsons, Barbara Tilley, Danilo Toni, Kazunori Toyoda, Nils Wahlgren, Joanna Wardlaw, William Whiteley, 
Gregory J del Zoppo, Colin Baigent†, Peter Sandercock†, Werner Hacke†; for the Stroke Thrombolysis Trialists’ Collaborative Group
Summary
Background Alteplase is eﬀ ective for treatment of acute ischaemic stroke but debate continues about its use after 
longer times since stroke onset, in older patients, and among patients who have had the least or most severe strokes. 
We assessed the role of these factors in aﬀ ecting good stroke outcome in patients given alteplase.
Methods We did a pre-speciﬁ ed meta-analysis of individual patient data from 6756 patients in nine randomised trials 
comparing alteplase with placebo or open control. We included all completed randomised phase 3 trials of intravenous 
alteplase for treatment of acute ischaemic stroke for which data were available. Retrospective checks conﬁ rmed that no 
eligible trials had been omitted. We deﬁ ned a good stroke outcome as no signiﬁ cant disability at 3–6 months, deﬁ ned by 
a modiﬁ ed Rankin Score of 0 or 1. Additional outcomes included symptomatic intracranial haemorrhage (deﬁ ned by 
type 2 parenchymal haemorrhage within 7 days and, separately, by the SITS-MOST deﬁ nition of parenchymal type 2 
haemorrhage within 36 h), fatal intracranial haemorrhage within 7 days, and 90-day mortality.
Findings Alteplase increased the odds of a good stroke outcome, with earlier treatment associated with bigger 
proportional beneﬁ t. Treatment within 3·0 h resulted in a good outcome for 259 (32·9%) of 787 patients who received 
alteplase versus 176 (23·1%) of 762 who received control (OR 1·75, 95% CI 1·35–2·27); delay of greater than 
3·0 h, up to 4·5 h, resulted in good outcome for 485 (35·3%) of 1375 versus 432 (30·1%) of 1437 (OR 1·26, 
95% CI 1·05–1·51); and delay of more than 4·5 h resulted in good outcome for 401 (32·6%) of 1229 versus 357 (30·6%) 
of 1166 (OR 1·15, 95% CI 0·95–1·40). Proportional treatment beneﬁ ts were similar irrespective of age or stroke 
severity. Alteplase signiﬁ cantly increased the odds of symptomatic intracranial haemorrhage (type 2 parenchymal 
haemorrhage deﬁ nition 231 [6·8%] of 3391 vs 44 [1·3%] of 3365, OR 5·55, 95% CI 4·01–7·70, p<0·0001; SITS-MOST 
deﬁ nition 124 [3·7%] vs 19 [0·6%], OR 6·67, 95% CI 4·11–10·84, p<0·0001) and of fatal intracranial haemorrhage 
within 7 days (91 [2·7%] vs 13 [0·4%]; OR 7·14, 95% CI 3·98–12·79, p<0·0001). The relative increase in fatal 
intracranial haemorrhage from alteplase was similar irrespective of treatment delay, age, or stroke severity, but the 
absolute excess risk attributable to alteplase was bigger among patients who had more severe strokes. There was no 
excess in other early causes of death and no signiﬁ cant eﬀ ect on later causes of death. Consequently, mortality at 
90 days was 608 (17·9%) in the alteplase group versus 556 (16·5%) in the control group (hazard ratio 1·11, 
95% CI 0·99–1·25, p=0·07). Taken together, therefore, despite an average absolute increased risk of early death from 
intracranial haemorrhage of about 2%, by 3–6 months this risk was oﬀ set by an average absolute increase in disability-
free survival of about 10% for patients treated within 3·0 h and about 5% for patients treated after 3·0 h, up to 4·5 h.
Interpretation Irrespective of age or stroke severity, and despite an increased risk of fatal intracranial haemorrhage 
during the ﬁ rst few days after treatment, alteplase signiﬁ cantly improves the overall odds of a good stroke outcome 
when delivered within 4·5 h of stroke onset, with earlier treatment associated with bigger proportional beneﬁ ts.
Funding UK Medical Research Council, British Heart Foundation, University of Glasgow, University of Edinburgh.
Copyright © Emberson et al. Open Access article distributed under the terms of CC BY.
Introduction
Intravenous alteplase (recombinant tissue plasminogen 
activator) is approved for the treatment of acute ischaemic 
stroke. Previous analyses of pooled data from randomised 
trials concluded that alteplase is beneﬁ cial when 
administered to some patients within 4·5 h, but that the 
magnitude of beneﬁ t diminishes with increasing 
treatment delay.1,2 However, uncertainties remain about 
the balance of beneﬁ t and risk when alteplase is given 
later after onset of symptoms, to older patients, or to 
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patients with very severe or mild strokes. Present 
guidance3–6 and marketing authorisation7,8 from Europe 
and elsewhere recommends the routine use of alteplase 
within 4·5 h of stroke onset but, in the USA, the Food 
and Drug Administration has approved the use of 
alteplase only within 3 h of stroke onset.9 Marketing 
authorisation for Europe7 and Australia,8 but not for the 
USA9 or Japan, cautions against the use of alteplase for 
severe and mild stroke. Marketing of alteplase in some 
European countries is also restricted to patients younger 
than 80 years7 (despite clinical guidelines based on 
observational studies that recommends its use in older 
patients3,10–12), whereas no such age restriction applies in 
many other countries, including the USA.
IST-313—designed to resolve some of these un-
certainties—included 3035 patients randomly assigned 
to alteplase or control up to 6 h after the onset of stroke. 
The principal investigators from IST-3 and other trials of 
alteplase13–19 agreed to make their individual-patient data 
available for analysis. The chief goal of this analysis was 
to explore the extent to which treatment delay aﬀ ected 
the eﬀ ect of alteplase and to establish whether age or 
stroke severity aﬀ ected treatment eﬀ ects. These analyses 
assessing potential eﬀ ect modiﬁ cation are only possible 
with individual patient data. Key secondary aims included 
estimating the eﬀ ect of alteplase on symptomatic 
intracranial haemorrhage and on 90-day mortality. 
Methods
Study design and inclusion criteria
We established a collaboration to undertake this meta-
analysis of individual patient data. We included all 
completed randomised phase 3 trials of intravenous 
alteplase for treatment of acute ischaemic stroke for which 
data were available. Retrospective checks conﬁ rmed that 
no eligible trials had been omitted. These checks included 
reference to a previous systematic review,20 an updated 
review of the Cochrane Stroke Group’s Specialised 
Register of Trials, and enquiry among collaborators and 
the manufacturer of alteplase (Boehringer Ingelheim, 
Ingelheim, Germany). Individual patient data were sought 
from eligible trials. Before accessing the combined 
dataset, the collaboration agreed on a statistical analysis 
plan.21 The study protocol is available online. 
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NINDS A NINDS B ECASS I ECASS II ATLANTIS A ATLANTIS B ECASS III EPITHET IST-3 TOTAL
Number randomised 291 333 620 800 142 613 821 101 3035 6756
Treatment delay (hours) 2·0 (0·6) 2·0 (0·6) 4·4 (1·1) 4·3 (1·1) 4·3 (1·1) 4·4 (0·8) 4·0 (0·4) 4·9 (0·8) 4·2 (1·2) 4·0 (1·2)
≤3·0 290 (>99%) 333 (100%) 87 (14%) 158 (20%) 22 (15%) 39 (6%) ·· ·· 620 (20%) 1549 (23%)
>3·0≤4·5 1 (<1%) ·· 233 (38%) 265 (33%) 53 (37%) 249 (41%) 788 (96%) 31 (31%) 1148 (38%) 2768 (41%)
>4·5 ·· ·· 295 (48%) 370 (46%) 67 (47%) 321 (52%) 6 (1%) 69 (68%) 1266 (42%) 2394 (35%)
Missing ·· ·· 5 (1%) 7 (1%) ·· 4 (1%) 27 (3%) 1 (1%) 1 (<1%) 45 (1%)
Age (years) 66 (11) 68 (12) 65 (12) 66 (11) 66 (13) 66 (11) 65 (12) 72 (13) 77 (12) 71 (13)
≤80 279 (96%) 289 (87%) 615 (>99%) 792 (99%) 142 (100%) 608 (>99%) 805 (98%) 76 (75%) 1418 (47%) 5024 (74%)
>80 12 (4%) 44 (13%) 5 (1%) 8 (1%) ·· 3 (<1%) 15 (2%) 25 (25%) 1617 (53%) 1729 (26%)
Missing ·· ·· ·· ·· ·· 2 (<1%) 1 (<1%) ·· ·· 3 (<1%)
Stroke severity (NIHSS) 14 (7) 15 (7) 12 (6) 12 (6) 13 (7) 11 (6) 10 (5) 13 (6) 12 (7) 12 (7)
0–4 16 (5%) 13 (4%) 34 (5%) 47 (6%) 10 (7%) 47 (8%) 98 (12%) 1 (1%) 400 (13%) 666 (10%)
5–10 78 (27%) 98 (29%) 189 (30%) 339 (42%) 57 (40%) 279 (46%) 389 (47%) 40 (40%) 1064 (35%) 2533 (37%)
11–15 68 (23%) 63 (19%) 183 (30%) 232 (29%) 28 (20%) 128 (21%) 163 (20%) 22 (22%) 601 (20%) 1488 (22%)
16–21 76 (26%) 78 (23%) 146 (24%) 113 (14%) 25 (18%) 106 (17%) 142 (17%) 29 (29%) 618 (20%) 1333 (20%)
≥22 45 (15%) 74 (22%) 28 (5%) 43 (5%) 20 (14%) 33 (5%) 18 (2%) 9 (9%) 352 (12%) 622 (9%)
Missing 8 (3%) 7 (2%) 40 (6%) 26 (3%) 2 (1%) 20 (3%) 11 (1%) ·· * 114 (2%)
Female 120 (41%) 142 (43%) 231 (37%) 331 (41%) 45 (32%) 250 (41%) 325 (40%) 43 (43%) 1570 (52%) 3057 (45%)
History of hypertension 188 (65%) 220 (66%) 258 (42%) 412 (52%) 87 (61%) 364 (59%) 514 (63%) 71 (70%) 1954 (64%) 4068 (60%)
History of stroke 49 (17%) 34 (10%) 83 (13%) 158 (20%) 31 (22%) 89 (15%) 89 (11%) 11 (11%) 699 (23%) 1243 (18%)
History of diabetes mellitus 64 (22%) 67 (20%) 81 (13%) 169 (21%) 27 (19%) 130 (21%) 129 (16%) 23 (23%) 388 (13%) 1078 (16%)
History of atrial ﬁ brillation 55 (19%) 60 (18%) 113 (18%) 188 (24%) 37 (26%) 97 (16%) 108 (13%) 42 (42%) 914 (30%) 1614 (24%)
Aspirin use 78 (27%) 93 (28%) 87 (14%) 196 (25%) 59 (42%) 211 (34%) 201 (24%) 30 (30%) 1306 (43%) 2261 (33%)
Weight (kg) 78 (17) 78 (19) 74 (12) 75 (14) 80 (20) 79 (18) 78 (15) 75 (19) 72 (15) 75 (16)
Systolic blood pressure (mmHg) 154 (21) 152 (21) 154 (23) 152 (21) 152 (24) 152 (21) 153 (21) 148 (19) 155 (24) 154 (22)
Diastolic blood pressure (mmHg) 85 (13) 85 (14) 87 (13) 84 (13) 81 (14) 82 (14) 84 (14) 78 (13) 82 (15) 83 (14)
Categorical data presented as n (%), continuous data presented as mean (SD). NINDS=National Institute of Neurological Disorders and Stroke; ECASS=European Cooperative Acute Stroke Study; 
ATLANTIS=Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke; EPITHET=Echoplanar Imaging Thrombolytic Evaluation Trial; IST=International Stroke Trial.  *In IST-3, 244 patients 
had their baseline NIHSS score predicted from other measurements recorded at their baseline assessment. Ignoring these patients, the numbers of IST-3 patients in each category of baseline NIHSS score above 
would be 385, 972, 531, 559 and 344 respectively.
Table 1: Baseline characteristics of patients in participating trials
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Outcomes
Our a-priori primary measure of treatment eﬃ  cacy was 
the proportion of patients who had a good stroke 
outcome, deﬁ ned by a modiﬁ ed Rankin score (mRS) 
of 0–1 (ie, symptom-free or residual symptoms with no 
loss of activity) at 3–6 months. 3-month assessments 
were to be used if available, but for IST-3 we used a 
6-month assessment because no 3-month assessment 
was done. We mapped the Oxford Handicap Scale 
outcome assessment used in IST-3 to equivalent 
mRS categories.
Key secondary outcomes were fatal intracranial 
haemorrhage within 7 days, any symptomatic intracranial 
haemorrhage, and 90-day mortality (separated by cause 
where possible). For a full list of secondary outcomes, see 
the pre-speciﬁ ed statistical analysis plan.21 Symptomatic 
intracranial haemorrhage was deﬁ ned in two ways: 
parenchymal haemorrhage of type 2 within 7 days16 and 
the SITS-MOST study22 deﬁ nition of type 2 parenchymal 
haemorrhage within 36 h. For IST-3, type 2 parenchymal 
haemorrhage within 7 days was approximated by 
signiﬁ cant brain parenchymal haemorrhage local or 
remote from the infarct, or signiﬁ cant haemorrhagic 
transformation of an infarct on brain imaging within 
7 days. The SITS-MOST deﬁ nition was approximated in 
IST-3 as evidence within 24 h of clinically signiﬁ cant 
deterioration or death together with evidence of either 
signiﬁ cant brain parenchymal haemorrhage (local or 
distant from the infarct) or signiﬁ cant haemorrhagic 
transformation of an infarct on brain imaging which, in 
the judgment of the adjudication panel, was likely to 
have worsened mass eﬀ ect or contributed to the burden 
of brain damage.
Statistical analysis
A full description of the analyses is provided in the pre-
speciﬁ ed statistical analysis plan.21 Brieﬂ y, we used 
logistic regression, stratiﬁ ed by trial, to model the 
common linear dependence of the log odds of a particular 
outcome on allocation to alteplase, treatment delay (a 
linear variable), age (a linear variable), baseline stroke 
severity (National Institutes of Health Stroke Scale 
[NIHSS] score, modelled by both linear and quadratic 
terms), and interactions between allocation to alteplase 
and each of these other baseline covariates. (The odds 
ratio estimates presented here are of course more 
extreme than corresponding risk ratio estimates would 
be, but have the advantage that they may be more 
generalisable among patients with diﬀ ering likelihood of 
a good stroke outcome.) We cross-checked individual 
data against previous publications. We imputed missing 
data with prespeciﬁ ed rules.21 We assessed the extent to 
which treatment delay, age, and stroke severity modiﬁ ed 
(individually or jointly) the proportional eﬀ ects of 
treatment by assessing the statistical signiﬁ cance of the 
relevant treatment interaction terms using likelihood 
ratio tests (ie, through comparison of minus twice the 
log-likelihood statistic between appropriate nested 
models). Other prespeciﬁ ed analyses included assess-
ment of treatment eﬀ ects separately according to 
categories of treatment delay that relate to present licence 
issues and previous trial time limits (≤3·0 h, >3·0≤4·5 h, 
>4·5 h), age (≤80 years, >80 years), and baseline stroke 
For the study protocol see 
http://www.ctsu.ox.ac.uk/
research/meta-trials/stt-1
Figure 1: Eﬀ ect of timing of alteplase treatment on good stroke outcome 
(mRS 0−1)
The solid line is the best linear ﬁ t between the log odds ratio for a good stroke 
outcome for patients given alteplase compared with those given control (vertical 
axis) and treatment delay (horizontal axis; pinteraction=0·016). Estimates are derived 
from a regression model in which alteplase, time to treatment, age, and stroke 
severity (handled in a quadratic manner) are included as main eﬀ ects but the only 
treatment interaction included is with time to treatment. Only 198 patients 
(159 from IST−3) had a time from stroke onset to treatment of more than 6 h. 
The white box shows the point at which the estimated treatment eﬀ ect crosses 1. 
The black box shows the point at which the lower 95% CI for the estimated 
treatment eﬀ ect ﬁ rst crosses 1·0. mRS=modiﬁ ed Rankin Scale. 
Figure 2: Eﬀ ect of alteplase on good stroke outcome (mRS 0−1), by treatment delay, age, and stroke severity
*For each of the three baseline characteristics, estimates were derived from a single logistic regression model 
stratiﬁ ed by trial, which enables separate estimation of the OR for each subgroup after adjustment for the other two 
baseline characteristics (but not for possible interactions with those characteristics). mRS=modiﬁ ed Rankin Scale.
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severity (NIHSS score 0–4, 5–10, 11–15, 16–21, ≥22). If we 
had data for the timing of events (eg, mortality within 
90 days), we estimated average relative risks with the 
hazard ratios (HRs) from analogous Cox proportional 
hazards regression models, with a test of the 
proportionality assumption provided by examination of 
the time-dependency of the Schoenfeld partial residuals.23 
All estimates of treatment eﬀ ect compared patients 
allocated alteplase with patients not allocated alteplase, 
and all treatment eﬀ ect size estimates are provided with 
their 95% CIs (calculated when necessary with bias-
corrected and accelerated-corrected bootstrap tech-
niques24) with p values less than 0·05 considered 
statistically signiﬁ cant. We did the analyses with SAS 
(version 9.3) and R (version 2.11.1).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
and responsibility for the decision to submit for
publication. 
Results
We obtained data for 6756 participants from nine trials 
(eight trials involving 3721 participants randomly 
assigned to alteplase versus placebo and one trial13 
involving 3035 participants assigned to alteplase versus 
open control; table 1); 3391 patients were given alteplase 
and 3365 were given control. Individual data were not 
available for ﬁ ve trials25–29 involving 270 participants. 
6602 (98%) of 6756 participants had complete baseline 
information for treatment delay, age, and stroke severity. 
None of our results changed substantially according to 
the choice of imputation for missing data, including 
exclusion of those with missing data (data not shown). 
On average, patients in IST-3 were 11 years older than 
were patients in the eight previous trials and received 
treatment 20 min later, but they had the same mean 
baseline stroke severity (appendix p 1). Strong 
relationships existed between patient age, treatment 
delay, and stroke severity in all trials (appendix p 4). 
Patients with severe strokes were treated earlier and—
particularly in IST-3—older patients had more severe 
strokes. In IST-3, but not previous trials, patients treated 
earlier also tended to be older than were patients treated 
later. Although 588 (19%) of 3035 participants in IST-3 
treated within 4·5 h of onset of stroke were aged 80 years 
or younger, most of these (372 [63%]) were enrolled 
before revised European guidance in January, 2009, 
recommending the routine use of alteplase for this 
group.4 Baseline characteristics were well balanced by 
treatment allocation for the pooled data (appendix p 2).
Overall, 2110 (31%) of 6756 patients achieved a good 
stroke outcome (mRS of 0 or 1) at 3–6 months (appendix 
p 3). Alteplase signiﬁ cantly increased the odds of a good 
outcome, with earlier treatment resulting in signiﬁ cantly 
Figure 3: Eﬀ ect of alteplase on a good stroke outcome (mRS 0−1) by age, with diﬀ erent treatment delays
Eﬀ ect of age on the interaction between treatment delay and treatment eﬀ ect p=0·08 (ie, not signiﬁ cant but, if 
anything, in the direction of it lengthening, not shortening, the period during which alteplase is eﬀ ective in older 
people). *All six estimates derived from a single stratiﬁ ed logistic regression model that enables the odds ratio to 
be estimated separately for each group (also adjusted for baseline National Institutes of Health Stroke Scale 
score). mRS=modiﬁ ed Rankin Scale.
Figure 4: Eﬀ ect of alteplase on fatal intracranial haemorrhage within 7 days by treatment delay, age, and 
stroke severity
*For each of the three baseline characteristics, estimates were derived from a single logistic regression model 
stratiﬁ ed by trial, which enables separate estimation of the OR for each subgroup after adjustment for the other 
two baseline characteristics (but not possible interactions with those characteristics). The overall eﬀ ect in all 
patients is the trial-stratiﬁ ed logistic regression estimate adjusted only for treatment allocation. 
NE=not estimable.
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Figure 5: Eﬀ ect of alteplase on 90-day mortality by follow-up period
Patients can only contribute to a particular risk period if they have already survived any preceding periods. 
*Estimated by Cox proportional hazards regression stratiﬁ ed by trial (and adjusted only for treatment allocation). 
†Includes 91 versus 13 deaths caused by intracranial haemorrhage (with evidence of parenchymal haemorrhage 
type 2; ﬁ gure 4) and 191 versus 191 deaths from other causes.
Hazard ratio 
(95% CI)*
Alteplase
(n=3391)
Days 1–7†
Days 8–30
Days 31–90
Total 90-day mortality
 282 (8·3%)
 178 (5·2%)
 148 (4·4%)
 608 (17·9%)
 204 (6·1%)
 188 (5·6%)
 164 (4·9%)
 556 (16·5%)
 1·39 (1·16−1·67)
 0·97 (0·79−1·20)
 0·92 (0·74−1·15)
 1·11 (0·99−1·25)
Control
(n=3365)
1·000·50 0·75 1·50 2·00
Alteplase worseAlteplase better
Test for varying log HR with increasing duration
of follow-up (p<0·0001)
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greater proportional beneﬁ t (p=0·016 for trend of 
increasing proportional beneﬁ t with earlier treatment; 
ﬁ gure 1). We estimated the time at which alteplase has no 
eﬀ ect to be 6·3 h (95% CI 5·0–13·8) and the time at which 
the lower 95% CI for the estimated treatment beneﬁ t ﬁ rst 
crossed 1·0 to be 5·1 h (ﬁ gure 1). When estimated in the 
three predeﬁ ned subgroups of treatment delay, alteplase 
signiﬁ cantly increased the odds of a good outcome when 
given within 3·0 h (OR 1·75, 95% CI 1·35–2·27; p<0·0001) 
or after 3·0 h up to 4·5 h (OR 1·26, 95% CI 1·05–1·51, 
p=0·0132), but not after 4·5 h (OR 1·15, 95% CI 0·95–1·40; 
p=0·15; ﬁ gure 2). The eﬀ ect of alteplase on a good 
outcome was chieﬂ y driven by treatment delay; after 
controlling for treatment delay, neither age nor severity of 
stroke contributed signiﬁ cant additional predictive value 
(appendix p 5). After allowing for diﬀ erences explained by 
treatment delay, the eﬀ ect of alteplase on a good outcome 
reported in IST-3 was consistent with that reported in the 
eight previous trials (p for inconsistency=0·92).
Age did not change the eﬀ ect of alteplase on odds of a 
good outcome (p=0·53; appendix p 5). The eﬀ ect of 
alteplase treatment was similar for patients aged 80 years 
or younger (mean treatment delay 4·1 h; 
990 [39%] vs 853 [34%]; OR 1·25, 95% CI 1·10–1·42, 
p<0·0001) and for those older than 80 years (mean 
treatment delay 3·7 h; 155 [18%] vs 112 [13%]; OR 1·56, 
95% CI 1·17–2·08, p=0·0023; ﬁ gure 2). We found no 
evidence that old age shortened the period during which 
alteplase could eﬀ ectively be given (p=0·08, in the 
direction of lengthening not shortening the period; 
ﬁ gure 3). Nor did we ﬁ nd clear evidence that stroke 
severity modiﬁ ed the eﬀ ect of alteplase (p=0·06). In 
particular, there was no evidence that alteplase was less 
eﬀ ective for patients who had had the least or most severe 
strokes (ﬁ gure 2, appendix p 5), reinforcing ﬁ ndings from 
one of the individual trials.30 
Alteplase increased the likelihood of symptomatic 
intracranial haemorrhage. Type 2 parenchymal haemor-
rhage within 7 days occurred in 231 (6·8%) of 3391 patients 
assigned alteplase versus 44 (1·3%) of 3365 assigned 
control (OR 5·55, 95% CI 4·01–7·70; p<0·0001) and 
SITS-MOST criteria type 2 parenchymal haemorrhage 
within 36 h occurred in 124 (3·7%) of 3391 versus 19 (0·6%) 
of 3365 (OR 6·67, 95% CI 4·11–10·84; p<0·0001). Fatal 
type 2 parenchymal haemorrhage within 7 days occurred 
in 91 (2·7%) patients assigned alteplase versus 13 (0·4%) 
assigned control (OR 7·14, 95% CI 3·98–12·79; p<0·0001). 
The proportional increase in risk of fatal intracranial 
haemorrhage was much the same, irrespective of 
treatment delay, age, or stroke severity (pinteraction>0·7 for all), 
but the absolute excess risk increased with increasing 
stroke severity (ﬁ gure 4). Alteplase did not increase the 
risk of other early causes of death (ie, those other than 
intracranial haemorrhage), and had no signiﬁ cant eﬀ ect 
on later causes of death (ﬁ gure 5). Consequently, the early 
excess mortality caused by intracranial haemorrhage did 
not translate into a signiﬁ cant excess of overall mortality 
at 90 days (608 [17·9%] vs 556 [16·5%], HR 1·11 
(95% CI 0·99–1·25); p=0·07; ﬁ gure 5). The trend towards 
a larger relative increase in 90-day mortality with greater 
treatment delay was not statistically signiﬁ cant 
(ptrend=0·22; ﬁ gure 6), although the statistical power to 
detect any true trend was limited by the number of 
deaths. The eﬀ ects of alteplase on symptomatic 
intracranial haemorrhage, fatal intracranial haemorrhage, 
and 90-day mortality reported in IST-3 were consistent 
with those reported in the eight previous trials (all 
p values for inconsistency >0·1).
Overall, therefore, despite an average absolute increase 
in risk of early death caused by intracranial haemorrhage 
of about 2%, by 3–6 months this was oﬀ set by an average 
absolute increase in disability-free survival (ie, mRS 0–1) 
of about 10% for patients treated within 3·0 h and about 
5% for patients treated between 3·1 and 4·5 h.
Discussion
Our data provide further evidence about the extent to 
which treatment delay alters the beneﬁ cial eﬀ ect of 
alteplase for acute ischaemic stroke. We provide clear 
evidence for improved odds of a good stroke outcome 
when treatment is started within 4·5 h of ischaemic 
stroke, with earlier treatment resulting in bigger 
proportional and absolute beneﬁ ts. The average beneﬁ t 
of alteplase might even extend beyond 4·5 h for some 
patients. The proportional beneﬁ ts were similar for 
patients aged older than 80 years compared with younger 
patients, and for patients with minor or severe strokes 
compared with other patients.
This average expected beneﬁ t from giving alteplase 
within 4·5 h occurred in spite of an average absolute 
increase in the early risk of fatal intracranial 
haemorrhage of around 2%. Since alteplase had no 
signiﬁ cant eﬀ ect on other early causes of death, or on 
later causes of death, by 90 days this 2% excess remained 
but was no longer statistically signiﬁ cant. Longer-term 
follow-up data are needed to test whether the eﬀ ect of 
alteplase on patients who survive the ﬁ rst week after 
their stroke have reduced long-term risk of death. 
Contrary to analyses of individual patient data done 
before IST-3,2 the trend towards a bigger relative risk of 
90-day mortality with increasing treatment delay was not 
Figure 6: Eﬀ ect of alteplase on 90-day mortality by treatment delay
*Estimated by Cox proportional hazards regression stratiﬁ ed by trial (and adjusted only for treatment allocation). 
HR=hazard ratio.
Hazard ratio 
(95% CI)*
Alteplase
(n=3391)
≤3·0 h
>3·0≤4·5 h
>4·5 h
Total 90-day mortality
 175 (22·2%)
 232 (16·9%)
 201 (16·4%)
 608 (17·9%)
 166 (21·8%)
 229 (15·9%)
 161 (13·8%)
 556 (16·5%)
 1·00 (0·81−1·24)
 1·14 (0·95−1·36)
 1·22 (0·99−1·50)
 1·11 (0·99−1·25)
Control
(n=3365)
1·000·50 0·75 1·50 2·00
Alteplase worseAlteplase better
Test for linear trend of log HR with 
increasing treatment delay (p=0·22)
See Online for appendix
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statistically signiﬁ cant in our analysis. However, if 
improvements in stroke outcome among survivors do 
lead to parallel improvements in mortality, then one 
would expect that long-term survival will be greatest 
among those treated earliest (ie, the group most likely to 
beneﬁ t from alteplase).
Our results support guidelines that recommend use of 
alteplase irrespective of age and up to 4·5 h after onset of 
stroke.3,10–12 In the USA, marketing authorisation has not 
been granted for use of altplase after 3·0 h,9 while in 
some European countries marketing authorisation limits 
the use of alteplase to patients aged 80 years or younger. 
In the present analysis, the lower limit of the 95% CI for 
the time at which the proportional beneﬁ t on mRS 0–1 
crossed the line of no eﬀ ect was 5·0 h, with statistically 
signiﬁ cant evidence of beneﬁ t in the prespeciﬁ ed subset 
of patients with treatment delay after 3·0 h, up to 4·5 h. 
In addition, we found no evidence that age modiﬁ ed 
either the proportional beneﬁ ts or the proportional 
hazards of alteplase, with clear evidence of overall beneﬁ t 
for mRS 0–1 among the 1729 patients aged older than 
80 years at randomisation. Nor was there evidence that 
older age shortened the period during which such 
beneﬁ ts were seen, according with a recent report.31
The availability of individual data for a large number of 
patients enabled us to make a more precise assessment 
of the relative eﬀ ects of alteplase than has been possible 
previously. We also included more than 1700 patients 
aged older than 80 years. The number of older patients 
with stroke is increasing as a proportion of the general 
population and as a proportion of those with stroke, so 
our analyses provide a reliable assessment of the eﬀ ects 
of alteplase in this group.32 Our analyses diﬀ er from 
previous pooled analyses of alteplase trials1,2 by including 
patients from IST-3, which almost doubles the number 
of patients available. They also diﬀ er from previous 
tabular meta-analyses20 through the use of individual 
data, which enables direct assessment of the potential for 
eﬀ ect modiﬁ cation. Our prespeciﬁ ed analysis plan 
safeguarded against the potentially inappropriate 
combination of data from IST-3 with those from the 
previous studies. In fact, the results from IST-3 were 
consistent with earlier trials after adjustment for the 
main diﬀ erences in patient characteristics.
Nonetheless, the open design of IST-3 and its broader 
deﬁ nition of signiﬁ cant bleeding might have inﬂ ated our 
estimate of the risk of parenchymal type 2 symptomatic 
haemorrhage. However, the number of such events 
associated with early neurological deterioration or death 
was small, limiting the potential for this to be a source of 
major bias. Furthermore, the overall results from IST-3 for 
symptomatic intracranial haemorrhage were similar to 
those estimated from previous trials. Patients in IST-3 
were also older on average than patients in the eight 
previous trials. However, this diﬀ erence provides one of 
the main strengths of our analysis—the ability to compare 
the eﬀ ect of alteplase reliably in old and young patients. 
Although unknown systematic diﬀ erences might also 
have existed between patients in IST-3 and patients in the 
other trials, any such characteristics would have to be 
strong determinants of treatment eﬀ ect (rather than just 
predictors of risk) to produce material bias in our overall 
results. Future work will investigate the potential 
independent eﬀ ect on treatment eﬀ ect of a range of other 
characteristics, including sex, blood pressure, and baseline 
imaging features. 
In conclusion, despite early increases in fatal intracranial 
haemorrhage, alteplase signiﬁ cantly improves the overall 
likelihood of a good stroke outcome at 3–6 months. The 
proportional beneﬁ t increases with earlier treatment 
and remains statistically signiﬁ cant up to at least 4·5 h 
after initial stroke symptoms, irrespective of age or 
stroke severity.
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